NO20082136L - 1,5-substituerte indol-2-yl-amidderivater - Google Patents

1,5-substituerte indol-2-yl-amidderivater

Info

Publication number
NO20082136L
NO20082136L NO20082136A NO20082136A NO20082136L NO 20082136 L NO20082136 L NO 20082136L NO 20082136 A NO20082136 A NO 20082136A NO 20082136 A NO20082136 A NO 20082136A NO 20082136 L NO20082136 L NO 20082136L
Authority
NO
Norway
Prior art keywords
amide derivatives
substituted indol
compounds
indol
substituted
Prior art date
Application number
NO20082136A
Other languages
English (en)
Inventor
Sven Taylor
Olivier Roche
Jean-Marc Plancher
Hans Richter
Matthias Heinrich Nettekoven
Valerie Runtz-Schmitt
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37814240&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082136(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20082136L publication Critical patent/NO20082136L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

Foreliggende oppfinnelse angår forbindelser med formel I hvor R1 til R4 og G samt farmasøytisk akseptable salter derav er som definert i beskrivelsen og kravene. Forbindelsene er anvendelige for behandling og/eller forebygging av sykdommer som er forbundet med moduleringen av H3 reseptorer. 1
NO20082136A 2005-11-30 2008-05-07 1,5-substituerte indol-2-yl-amidderivater NO20082136L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05111478 2005-11-30
PCT/EP2006/068655 WO2007062999A2 (en) 2005-11-30 2006-11-20 1,5-substituted indol-2-yl amide derivatives

Publications (1)

Publication Number Publication Date
NO20082136L true NO20082136L (no) 2008-06-30

Family

ID=37814240

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082136A NO20082136L (no) 2005-11-30 2008-05-07 1,5-substituerte indol-2-yl-amidderivater

Country Status (18)

Country Link
US (1) US7745479B2 (no)
EP (1) EP1957479B1 (no)
JP (1) JP4879997B2 (no)
KR (1) KR101124156B1 (no)
CN (1) CN101316840B (no)
AR (1) AR057989A1 (no)
AT (1) ATE500244T1 (no)
AU (1) AU2006319234B2 (no)
BR (1) BRPI0619268A2 (no)
CA (1) CA2630314A1 (no)
DE (1) DE602006020482D1 (no)
ES (1) ES2359739T3 (no)
IL (1) IL191314A (no)
NO (1) NO20082136L (no)
RU (1) RU2008126391A (no)
TW (1) TWI333490B (no)
WO (1) WO2007062999A2 (no)
ZA (1) ZA200804301B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006319235A1 (en) * 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 5-substituted indole-2-carboxamide derivatives
DE602006021626D1 (de) * 2005-11-30 2011-06-09 Hoffmann La Roche 1,1-dioxo-thiomorpholinyl-indolyl-methanon-derivate zur verwendung als h3-modulatoren
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
WO2008083124A1 (en) 2006-12-28 2008-07-10 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
US7507736B2 (en) * 2007-02-07 2009-03-24 Hoffmann-La Roche Inc. Indol-2-yl-piperazin-1-yl-methanone derivatives
CA2705947C (en) * 2007-11-16 2016-08-09 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
US8129390B2 (en) * 2007-12-12 2012-03-06 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds and methods for using the same
JP5658138B2 (ja) 2008-04-23 2015-01-21 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害の処置のためのカルボキサミド化合物
US9394294B2 (en) * 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8765737B1 (en) * 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
MX2013000733A (es) 2010-07-23 2013-05-30 Demerx Inc Composiciones de noribogaina.
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
CA2851087C (en) 2011-10-07 2019-09-24 Takeda Pharmaceutical Company Limited 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
EP2788003A4 (en) 2011-12-09 2015-05-27 Demerx Inc PHOSPHATESTER OF NORIBOGAIN
AU2013212139A1 (en) 2012-01-25 2014-06-26 Demerx, Inc. Synthetic voacangine
JP2016508979A (ja) 2012-12-20 2016-03-24 デメレックス， インコーポレイテッド 置換ノルイボガイン
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
EP3071205B1 (en) 2013-11-18 2020-02-05 Forma Therapeutics, Inc. Benzopiperazine compositions as bet bromodomain inhibitors
MX370535B (es) 2013-11-18 2019-12-17 Forma Therapeutics Inc Compuestos de tetrahidroquinolina como inhibidores del bromodominio extra terminal y bromo (bet) y el uso de los mismos en el tratamiento de cáncer.
CN105523986A (zh) * 2015-12-30 2016-04-27 江汉大学 一种外排泵抑制剂n-氢-2-芳基吲哚及其衍生物的合成方法
CN115340460A (zh) * 2022-09-21 2022-11-15 江西亚太科技发展有限公司 一种Reissert吲哚合成反应中间体的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
US5246960A (en) * 1984-12-21 1993-09-21 Hoffmann-La Roche Inc. Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA2035972C (en) * 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
TR200100472T2 (tr) 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri ile sitozan içeren farmasötik bileşimler
CN1170534C (zh) 1998-08-14 2004-10-13 霍夫曼-拉罗奇有限公司 含有脂酶抑制剂的药物组合物
MXPA01009814A (es) 1999-03-29 2002-04-24 Hoffmann La Roche Activadores de la glucoquinasa.
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
JP2006512404A (ja) * 2002-10-22 2006-04-13 グラクソ　グループ　リミテッド Ｈ３受容体リガンドとしてのアリールオキシアルキルアミン誘導体
CA2569611C (en) * 2004-06-21 2012-12-11 F. Hoffmann-La Roche Ag Indole derivatives as histamine receptor antagonists
DE602006021626D1 (de) * 2005-11-30 2011-06-09 Hoffmann La Roche 1,1-dioxo-thiomorpholinyl-indolyl-methanon-derivate zur verwendung als h3-modulatoren
US7507736B2 (en) * 2007-02-07 2009-03-24 Hoffmann-La Roche Inc. Indol-2-yl-piperazin-1-yl-methanone derivatives

Also Published As

Publication number Publication date
KR20080076980A (ko) 2008-08-20
TW200804340A (en) 2008-01-16
WO2007062999A3 (en) 2007-07-26
ZA200804301B (en) 2009-04-29
CN101316840B (zh) 2012-08-08
AU2006319234B2 (en) 2012-01-19
JP2009517433A (ja) 2009-04-30
US20070123515A1 (en) 2007-05-31
KR101124156B1 (ko) 2012-03-23
TWI333490B (en) 2010-11-21
JP4879997B2 (ja) 2012-02-22
ES2359739T3 (es) 2011-05-26
US7745479B2 (en) 2010-06-29
EP1957479B1 (en) 2011-03-02
AR057989A1 (es) 2008-01-09
WO2007062999A2 (en) 2007-06-07
AU2006319234A1 (en) 2007-06-07
CN101316840A (zh) 2008-12-03
CA2630314A1 (en) 2007-06-07
BRPI0619268A2 (pt) 2011-09-20
RU2008126391A (ru) 2010-01-10
DE602006020482D1 (de) 2011-04-14
EP1957479A2 (en) 2008-08-20
ATE500244T1 (de) 2011-03-15
IL191314A (en) 2012-06-28

Similar Documents

Publication Publication Date Title
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
NO20082096L (no) Azaindol-2-karboksamidderivativer
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
NO20082939L (no) Sykloheksyl piperasinyl metanon derivater og anvendelse av disse som histamin H3 reseptor modulatorer
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
TW200612936A (en) Indole derivatives
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
WO2008040649A3 (en) Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
DE602006010540D1 (de) (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl)-amine mit aktivität am 5-ht-rezeptor
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
TW200637817A (en) 5-aminoindole derivatives
DE602006014022D1 (de) 5-substituierte indol-2-carbonsäureamidderivate
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
MX2007004910A (es) Nuevos derivados de indol o benzimidazol.
ATE488510T1 (de) Heterocyclische derivate, deren herstellung und therapeutische verwendung
NO20080553L (no) Azinyl-3-sulfonylindazolderivater som 5-hydroksytrypyamin-6 ligander

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application